Ophthalmology Times Europe E-News:
Having trouble viewing this e-mail? Click here.
You are subscribed to Ophthalmology Times Europe.
Ophthalmology Times Europe E-News
Modern Medicine Network
 
 
 
 
In this issue
Retina
Ocular surface
Cornea
 
 
Survey

Do you currently use CXL therapy in your practice?

Click here to vote

You can now follow us on Twitter:
www.twitter.com/oteurope

Contact Us
Click here to contact Felicity Thomas, editor.


January 8, 2014
Steroid-induced CSC
Steroid-induced CSC may only occur in vulnerable patients
Steroid-induced central serous chorioretinopathy (CSC) may only occur in select patients who are vulnerable, rather than having a dose-dependent effect, according to a recently published study. More...
Autologous serum eye drops
AS eye drops improve ocular surface dryness and decrease epithelial damage
Autologous serum (AS) eye drops on the ocular surface of patients with bilateral severe dry eye improved not only ocular surface dryness, but decreased damage of the epithelium as well, as measured by clinical, laboratory, and subjective criteria, according to results from a recent study. More...
CXL benefits progressive keratoconus
CXL therapy benefits patients with progressive keratoconus
Collagen crosslinking (CXL) in patients with progressive keratoconus was found to be effective after 2 years in improving uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), topographic metrics, and most corneal higher-order aberrations, according to recent data. More...
Choosing and using the AcrySof IQ ReSTOR IOL family
Customize
d options for individual patients. Read more:
The Safety of anti-VEGF Therapy
Under the microscope, in trials and in clinical practice. Read more: